Dual-target CAR-NK cells not checked

Beijing Biotech

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
8 active
8 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Route: IV infusion. Schedule: single infusion on Day 0; optional second infusion on Day 7 in the absence of dose-limiting toxicity (DLT) and with adequate clinical status.”In the company’s words, NCT07486089 on ClinicalTrials.gov
Tested for
HER2-positive Breast Cancer (2 trials), Non-Small Cell Lung Cancer (2 trials), Epithelial Ovarian Cancer (2 trials), Primary Peritoneal Carcinoma (2 trials), Fallopian Tube Carcinoma (2 trials), Recurrent or Refractory Disease After Standard Therapies (2 trials), Glioblastoma (2 trials), Malignant Glioma (2 trials) and 11 more
Main trialPhase 1/2
“This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.”In the company’s words, NCT07486089 on ClinicalTrials.gov
Other names
Dual-target CAR-NK cell product

Other drugs for HER2-positive Breast Cancer

All 396 drugs for HER2-positive Breast Cancer

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 14 Feb 2027 Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/2Recruiting 14 Feb 2027 Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/2Recruiting 17 Feb 2027 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Phase 1/2Recruiting 14 Mar 2027 Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/2Recruiting 14 Mar 2027 Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Phase 1/2Recruiting 14 Jun 2027 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Phase 1Recruiting 18 Feb 2027 Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1Recruiting 14 Apr 2027 Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Dual-target CAR-NK cells

Following is part of Solo: you see every change to Dual-target CAR-NK cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in